Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
 3 Months Ended 6 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Mar. 31, 2012
Mar. 31, 2011
REVENUES        
Neurometric information services $ 25,200 $ 29,200 $ 57,200 $ 56,400
Clinical services 188,900 162,600 341,200 283,200
Total revenues 214,100 191,800 398,400 339,600
OPERATING EXPENSES        
Cost of neurometric services revenues 35,900 36,500 75,100 72,500
Research 67,400 119,300 137,100 330,300
Product development 162,800 116,400 275,300 260,800
Sales and marketing 315,000 347,500 645,100 594,300
General and administrative 1,051,000 1,079,200 2,112,000 2,133,100
Total operating expenses 1,632,100 1,698,900 3,244,600 3,391,000
OPERATING LOSS (1,418,000) (1,507,100) (2,846,200) (3,051,400)
OTHER INCOME (EXPENSE):        
Interest expense, net (1,135,700) (1,329,100) (2,617,700) (3,956,100)
Financing fees (106,200) (146,700) (151,500) (289,300)
Offering costs (900) 0 (7,700) 0
Gain (Loss) on derivative liabilities (5,733,700) (3,963,400) (5,501,700) 254,200
Total other expense (6,976,500) (5,439,200) (8,278,600) (3,991,200)
LOSS BEFORE PROVISION FOR INCOME TAXES (8,394,500) (6,946,300) (11,124,800) (7,042,600)
Income taxes 0 0 900 1,300
NET LOSS $ (8,394,500) $ (6,946,300) $ (11,125,700) $ (7,043,900)
NET LOSS PER SHARE:        
Basic (Note 7) (in dollars per share) $ (4.48) $ (3.72) $ (5.94) $ (3.77)
Diluted (Note 7) (in dollars per share) $ (4.48) $ (3.72) $ (5.94) $ (3.77)
WEIGHTED AVERAGE SHARES OUTSTANDING:        
Basic (in shares) 1,873,948 1,867,464 1,873,766 1,867,690
Diluted (in shares) 1,873,948 1,867,464 1,873,766 1,867,690